相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low-dose Btk inhibitors: an 'aspirin' of tomorrow?
Bernard Payrastre et al.
HAEMATOLOGICA (2021)
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
Claire L. Langrish et al.
JOURNAL OF IMMUNOLOGY (2021)
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
Philipp von Hundelshausen et al.
CANCERS (2021)
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study
D. F. Murrell et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
Martin Kaul et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors
Philipp von Hundelshausen et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Daniela Angst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Fast and Clean BTK Inhibitor
Ronen Gabizon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors
Vincent Sibaud et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia
Naohiro Sekiguchi et al.
CANCER SCIENCE (2020)
A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors
Phillip L. R. Nicolson et al.
PLATELETS (2020)
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
Raji E. Joseph et al.
ELIFE (2020)
Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib
Viola Denzinger et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Kristina Busygina et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
David J. Kuter et al.
BLOOD (2019)
Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?
Luise Goldmann et al.
BLOOD ADVANCES (2019)
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans
Kristina Busygina et al.
BLOOD (2018)
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
Jun Chen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
John C. Byrd et al.
Oncotarget (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Alexander P. Bye et al.
BLOOD ADVANCES (2017)
X-Linked Agammaglobulinaemia: Outcomes in the modern era
Ben Shillitoe et al.
CLINICAL IMMUNOLOGY (2017)
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
Patrick F. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis
Holly Payne et al.
BLOOD (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw et al.
NATURE CHEMICAL BIOLOGY (2015)
Why and how to eliminate spontaneous platelet aggregation in blood measured by multiple electrode aggregometry
V. G. Bampalis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic Plaques
Armin J. Reininger et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Value of a single preoperative PFA-100® measurement in assessing the risk of bleeding in patients taking cyclooxygenase inhibitors and undergoing total knee replacement
K. F. J. Ng et al.
BRITISH JOURNAL OF ANAESTHESIA (2009)
Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo
Christian Schulz et al.
BASIC RESEARCH IN CARDIOLOGY (2008)
Use of the PFA-100 (TM) closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis
J.-L. Reny et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Clinical Utility of the PFA-100
Emmanuel J. Favaloro
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2008)
Multiple electrode aggregometry:: A new device to measure platelet aggregation in whole blood
Orsolya Toth et al.
THROMBOSIS AND HAEMOSTASIS (2006)
Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI
S Penz et al.
FASEB JOURNAL (2005)
Tec regulates platelet activation by GPVI in the absence of Btk
BT Atkinson et al.
BLOOD (2003)
Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females
T Futatani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Platelet function analysis with PFA-100® in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample
KW von Pape et al.
THROMBOSIS RESEARCH (2000)
分享论文
